News Archive

2020

May

Media Release / May 27, 2020

Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)

Read More
Media Release / May 27, 2020

Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

Read More
2021

May

Media Release / May 01, 2021

Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

Read More

April

Media Release / Apr 23, 2021

Novartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in children with moderate to severe plaque psoriasis

Read More
Colorful rock layers with showing blue, brown, and tan
Story / Apr 21, 2021

Building clinical trial diversity for long-term equity

Vas Narasimhan reflects on how to increase diversity in clinical trials

Read More
Media Release / Apr 16, 2021

Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS

Read More
Media Release / Apr 16, 2021

Novartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosis

Read More
Media Release / Apr 12, 2021

Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

Read More

March

Media Release / Mar 17, 2021

Novartis awards $450,000 to eight nonprofit organizations through the STEP Program™

Read More
Story / Mar 17, 2021

The STEP Program™: Supporting Solutions from Patient Advocacy Organizations

Read More

Related Links